tradmap

MRNA Moderna

$63.97 +3.22%

S&P 500 Companies

Held by SPYVOOIVV

Healthcare · Biological Products, (No Diagnostic Substances)

Moderna (MRNA) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $25.4 billion. Shares last traded at $63.97, 5.4% below their 52-week high. Over the past year the stock is up 150.6%. Net profit margin is -145.2%, below the peer median of 6.3%. Revenue declined 39.9% year over year.

Market Cap
$25.4B
Shares Out
396.8M
EPS (TTM)
$-15.71
P/E Ratio
P/S Ratio
13.06
P/B Ratio
3.43
Dividend / Share
Dividend Yield
52-Week High
$67.65
52-Week Low
$22.28
Volume
658,427
Avg Vol (3m)
276,321.476

Performance

1W
+28.83%
1M
+39.86%
3M
+22.18%
6M
+114.00%
YTD
+107.21%
1Y
+150.65%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
74.93
SMA (50)
$50.23
SMA (200)
$39.26
Price vs SMA50
+27.34%
Price vs SMA200
+62.93%
ATR (14)
$3.76

Financials

Revenue
$1.9B
Net Income
$-2822M
Gross Margin
Operating Margin
-158.1%
Net Margin
-145.2%
Return on Equity
-38.1%
Return on Assets
-24.6%
Current Ratio
2.41
Debt / Equity
0.08
Revenue Growth (YoY)
-39.9%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-3.40 2026-05-01
FY 2025 $-7.26 2026-02-20
Q3 2025 $-5.15 2025-11-06
Q2 2025 $-4.64 2025-08-01
Q1 2026 $-2.52 2026-05-01
FY 2025 $-9.28 2026-02-20

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

MRNA vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
13.06 / 5.21 med
+150% premium
Net margin vs peers
-145.2% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.